Personalis, Inc. 2021 Form 10-K Summary
Business context and reporting period
Personalis provides genomic sequencing and data-analysis services focused on precision oncology, clinical and companion diagnostics, biopharmaceutical research, and population genomics. The filing covers the fiscal year ended December 31, 2021; the source does not provide a separate fourth-quarter income statement.
The company launched NeXT Personal in December 2021, a tumor-informed liquid-biopsy assay designed to detect minimal residual disease and recurrence. Oncology revenue grew rapidly, while the U.S. Department of Veterans Affairs Million Veteran Program (VA MVP) remained the largest revenue source.
Key financial metrics
| Metric | 2021 | 2020 | Change |
|---|---|---|---|
| Revenue | $85.5 million | $78.6 million | +9% |
| Gross profit | $31.7 million | $20.1 million | +58% |
| Gross margin | 37.0% | 25.6% | +11.4 percentage points |
| Operating loss | $(65.4) million | $(42.1) million | Loss widened |
| Operating margin | (76.4%) | (53.6%) | Down 22.8 percentage points |
| Net loss | $(65.2) million | $(41.3) million | Loss widened 58% |
| Basic and diluted loss per share | $(1.49) | $(1.20) | Worsened |
| Net cash used in operations | $(70.8) million | $(42.7) million | Use increased |
| Cash and short-term investments | $287.1 million | $203.3 million | +41% |
| Total debt | $3.5 million | None reported | New equipment and software loans |
- Revenue from the VA MVP was $45.7 million, or 53% of total revenue, down 19% from 2020. Revenue from all other customers increased 77% to $39.8 million.
- NeXT Platform revenue was $27.9 million, compared with $8.2 million in 2020. Excluding VA MVP revenue, NeXT Platform products represented more than two-thirds of revenue.
- Research and development expense increased 73% to $49.3 million, and selling, general and administrative expense increased 42% to $47.7 million.
- Cost of revenue declined 8% to $53.8 million despite higher revenue, reflecting customer mix and laboratory-processing efficiencies.
- Stock-based compensation increased to $14.4 million from $8.2 million.
- Capital expenditures were $11.1 million in 2021. Financing cash flow of $169.7 million primarily reflected $162.3 million of net proceeds from the January 2021 follow-on offering.
- At year-end, cash and cash equivalents were $105.6 million, short-term investments were $181.5 million, working capital was $286.9 million, and total stockholders’ equity was $310.3 million.
- Operating lease liabilities totaled $56.5 million, and total future operating lease payments were $84.6 million. The company entered into a 13.5-year lease for a 100,000-square-foot Fremont facility.
Material changes versus the prior comparable period
- Total revenue increased 9%, but the composition shifted materially toward oncology and non-VA customers. VA MVP revenue fell by $10.5 million, while all other customer revenue rose by $17.3 million.
- Gross margin improved substantially because of favorable customer mix and improved laboratory utilization and processing efficiency.
- Operating expenses rose substantially as Personalis expanded research and development, automation, commercial capabilities, headcount, and the Fremont facility.
- Net loss increased by $23.9 million, and operating cash use increased by $28.2 million, reflecting continued investment and higher working-capital needs.
- The company raised $162.3 million net through its January 2021 follow-on offering and ended the year with significantly greater liquidity.
- Debt increased from none reported at year-end 2020 to $3.5 million of carrying value for noninterest-bearing equipment and software financing arrangements.
- Customer concentration remained high: the VA MVP accounted for 53% of revenue, Natera accounted for 10%, and the top five customers accounted for 84%.
Guidance, outlook, commentary, risks, and unusual items
- Management stated that no VA MVP request-for-proposal process is expected in 2022 and that no new VA MVP orders are expected beyond the current contract. The remaining VA MVP backlog was $7.6 million at December 31, 2021, expected to be recognized within the first three quarters of 2022.
- Management expects VA MVP revenue to decline significantly in 2022 and future periods unless a new task order or services agreement of comparable size is obtained. Management expects all other customers to constitute the majority of 2022 revenue based on 2021 orders.
- No formal consolidated revenue or earnings guidance is provided in the filing. The company expects continued net losses and increased research and development, selling and administrative spending.
- Personalis expects 2022 capital expenditures of $55 million to $65 million, including $45 million to $50 million for Fremont leasehold improvements, renovations, administrative costs, and related expenditures, net of expected landlord reimbursements.
- Management believes existing cash, cash equivalents, short-term investments, and anticipated operating cash receipts will fund capital and operating needs for at least the next 12 months. The company also established a $100 million at-the-market equity program in January 2022, with no shares sold under the program as of the filing.
- Key risks include dependence on the VA MVP and Natera, continued losses and cash burn, uncertain adoption and reimbursement for diagnostic products, FDA and laboratory regulatory changes, COVID-19 disruption, reliance on Illumina as a principal sequencing supplier, cybersecurity and privacy exposure, intellectual-property claims, and execution risk related to the Fremont expansion.
- Customer deposits were approximately $3.8 million, including $3.3 million from one customer, and could require repayment if future service levels are reduced or contracts are canceled.
- The company reported no material legal proceedings. Deloitte & Touche LLP issued unqualified opinions on the financial statements and internal control over financial reporting; no critical audit matters were identified.
Most important facts for an investor to verify
- Whether Personalis replaces or materially reduces the $45.7 million VA MVP revenue base after the $7.6 million remaining backlog is recognized.
- Whether growth in NeXT Platform, Natera, pharmaceutical, and clinical-center business offsets the VA MVP decline.
- The pace of cash burn relative to the $287.1 million liquidity balance and the timing and final cost of Fremont capital expenditures.
- Gross-margin sustainability as customer mix changes and laboratory capacity expands.
- Commercial adoption, clinical validation, reimbursement, and regulatory status of NeXT Personal, NeXT Dx, and other diagnostic offerings.
- Customer concentration, Natera volume commitments, and the absence of minimum purchase obligations under the Natera agreement.
- Availability and terms of Illumina sequencing equipment, reagents, maintenance, and related agreements as they approach expiration.
- Potential dilution from the $100 million at-the-market program, equity compensation, and approximately 7.2 million potentially dilutive securities excluded from 2021 diluted loss-per-share calculations.